PRMT6 and glioblastoma: In addition, to further verify the role of PRMT6 in glioblastoma invasiveness, we used PRMT6 inhibitors (EPZ020411) to treat glioblastoma cells for 48 h and repeated the above experiments and obtained similar results, indicating that inhibition of PRMT6 can weaken the invasiveness and migration of glioblastoma cells (Fig. 2G–J).